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Polycystic ovary syndrome (PCOS) is an endocrine disorder that 
manifests in an array of symptoms that varies from one woman 
to another. Common symptoms of PCOS include menstrual 
irregularities, excess hair growth (hirsutism), acne, and weight gain 
(Escobar-Morreale, 2018); these are driven by an excess of androgens 
(hyperandrogenism) and insulin resistance, which are central features 
of the condition. Historically PCOS was considered a reproductive 
disorder acquired by adult women, but it is now understood to be a 
lifelong metabolic condition (El Hayek et al., 2016).
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PCOS is estimated to affect 6 to 18% of women, depending 
on the diagnostic criteria used (Teede et al., 2010; March et al., 
2010). However, in older generations of women, diagnosis typically 
occurred only if women sought fertility treatment (Lujan et al., 
2008). Better recognition of the syndrome across clinical specialties, 
and less reluctance by women to disclose symptoms, has improved 
diagnosis in women currently of reproductive age. 
Relatively little is known about the progression of health status 
of older women with PCOS. Available evidence suggests that they 
may have relatively early onset of diabetes and other cardiometabolic 
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disorders, only partly accounted for by the tendency for women with 
PCOS to be obese (Daan et al., 2014). There is some evidence that 
women with PCOS perceive their health to be poor (Bazarganipour 
et al., 2013) and their lifestyle behaviours are less healthy than those 
of their peers (Lin et al., 2018) which may also contribute to age-
related deterioration in health (Echiburu et al., 2016). Among young 
women with PCOS, poor mental health and emotional distress has 
consistently been documented (Barry et al., 2011; Blay et al., 2016; 
Dokras et al., 2011, 2012; Veltman-Verhulst et al., 2012) but it is 
unclear whether psychological problems prevail with age. 
Most of the published research on PCOS has been based on 
highly selected groups of women drawn from clinics. Such groups 
are known to comprise of women with the most severe disease states 
(Azziz et al., 2016). Consequently, information is lacking about 
women with PCOS in unselected populations across the lifespan 
(Azziz et al., 2016). This impedes progress in understanding the 
burden of this condition in the community and the presentation 
of phenotypes of PCOS, particularly in peri- and post-menopausal 
women. 
The aims of this paper are two-fold. First, to describe the 
prevalence of self-reported, doctor-diagnosed PCOS across 10-year 
age groups in a representative, community-based sample of women 
aged 15 to 95 years. Second, we aimed to explore the extent to which 
women with PCOS experienced increased physical, metabolic and 
psychological comorbidities compared to women without PCOS, 
and whether any excess risk persists as women age.
METHODS
This study utilised data from the 2015 South Australian Health 
Omnibus Survey, an annual, population-based survey of 
approximately 3000 males and females, designed to be representative 
of the South Australian population aged over 15 years (Wilson et al., 
1992). A different sample of respondents are selected each year. 
Details of the methodology and characteristics of the sample have 
been reported elsewhere (Wilson et al., 1992). Briefly, participants 
were identified using a multistage process of clustered, self-
weighted sampling of households in metropolitan and country 
areas with populations of more than 1000. Data were weighted by 
5-year age groups, sex, and area (metropolitan Adelaide and rural/
remote South Australia) to the most recent Estimated Residential 
Population for South Australia (Australian Bureau of Statistics, 
2013) and by the probability of selection within the household size to 
provide population estimates. Interviews were conducted in person 
by trained interviewers. These analyses use only data from female 
respondents, and 2015 was the first year that questions about PCOS 
were asked. 
Measures
Diagnosis of polycystic ovarian syndrome
The presence of PCOS was determined by asking women “Have you 
ever been diagnosed with Polycystic Ovary Syndrome?” This implied 
that the women had visited a doctor and received a diagnosis. 
Demographic and lifestyle characteristics 
Demographic variables were used for weighting purposes and to 
describe the sample. Participants reported their country of birth, 
age, marital status, household size, highest education level achieved, 
annual household income, current employment status and whether 
they were of Aboriginal or Torres Strait Islander origin.
In the analyses age was classified in two ways: 10-year age 
groups (15–24, 25–34, 35–44, 45–54, 55–64, ≥ 65 years), or two age 
categories, < 45 years and ≥ 45 years. The latter subgroups distinguish 
women according to reproductive and peri-/post-menopausal years. 
Women self-reported their height (cm) and weight (kg). 
Body mass index (BMI) was calculated (weight/height2) and 
then categorised using World Health Organization criteria for 
respondents ≥18 years (BMI ≥ 25 kg/ m2 for overweight and obesity, 
BMI ≥ 30 kg/m2 for obesity (World Health Organization, 2000)) 
and corresponding categories for respondents aged < 18 years (Cole 
et al., 2000).
Women reported their current physical activity status (whether 
they exercised >3 days/week) and current smoking status (affirmed 
if they smoked daily or occasionally). Women were also asked if they 
had ever been pregnant.
Physical, metabolic and psychological comorbidities 
Metabolic and other chronic conditions were assessed by asking 
respondents if they had ever been told by a doctor that they had 
diabetes, cardiovascular disease (CVD) (specifically heart attack, 
angina, stroke and/or atrial fibrillation), arthritis (osteoarthritis, 
rheumatoid arthritis or any other type), asthma (affirmed if currently 
have asthma), or had been prescribed medication for high blood 
pressure or cholesterol. 
Self-rated health status (dichotomised to poor/fair or good/very 
good/excellent) was derived from the first question of the Short Form 
12 (SF12) (Ware et al., 1996): a generic, multipurpose questionnaire 
concerning views on health status over the past 4 weeks). Women 
were classified as having clinical symptoms of depression if they had 
scored below 42 on the Mental Component Summary of the SF12 
(Silveira et al., 2005). Participants also reported any current use of 
antidepressant medications. 
Statistical analysis
The prevalence of diagnosed PCOS was calculated for the overall 
sample. Sociodemographic and lifestyle characteristics of women 
diagnosed with PCOS were then compared with those without 
PCOS using Pearson’s chi-square tests for association for categorical 
data. The prevalence of PCOS in each 10-year age strata with 95% 
confidence intervals (CIs) was plotted.
Women were subgrouped by age (< 45 years or ≥ 45 years) 
to indicate the end of reproductive years and commencement 
of perimenopause, and differences in the frequency of physical, 
metabolic and psychological comorbidities and fair/poor self-
assessed health by PCOS status were examined using Pearson’s chi-
square tests for association (and Fisher’s exact correction where cell 
sizes were less than 5). A p-value of < 0.05 was considered significant. 
Overall differences in the risk of physical, metabolic and 
psychological comorbidities and poor/fair self-assessed health 
between women with and without PCOS were examined using 
logistic regression. Odds ratios (OR) and 95% CI were generated in 
unadjusted models, then adjusted for age (six categories, 10-year age 
bands), and age and BMI status (continuous), as both of these factors 
contribute independently to the risk of chronic health conditions 
(Xu et al., 2018). All analyses were conducted using SPSS Version 
22.0 (SPSS, 1989–2016).
RESULTS
In 2015, 1527 women aged ≥15 years completed the survey, with an 
overall response rate of 57.3%. Seventeen women did not answer the 
question on PCOS (1.1%) so were excluded from further analyses. 
Table 1 describes the sociodemographic and lifestyle characteristics 
of the sample (n = 1509). The mean age was 47.4 years (SD 19.3), 
most respondents were born in Australia (73.7%) and were married 
or living with a partner (63.2%). Approximately one quarter had a 
tertiary (university) qualification (24.9%). Eight-five women (5.6%, 
95% CI 4.6–6.9%) reported a diagnosis of PCOS. There were no 






































































































differences in the sociodemographic characteristics of women who 
reported PCOS when compared with those who did not, however 
women with PCOS tended to be older (p = 0.07) and were more 
likely to have been pregnant (p = 0.09) (Table 1). 
Women with PCOS had significantly higher BMI (mean BMI: 
29.8 ± 8.7 vs. 26.8 ± 6.4 kg/m2, p = 0.005), hence were more likely to 
be overweight or obese (p = 0.03). Prevalence of PCOS was higher 
amongst women who were overweight (5.9%, 95% CI 3.9–8.8) and 
obese (7.9%, 95% CI 5.5–11.2%) (p = 0.005) compared to normal 
weight) (5.4%, 95% CI 3.1–6.6). Women with PCOS were also more 
likely to be current smokers (p = 0.04).
The prevalence of PCOS peaked in the 35 to 44 year age group 
at 9.1% (95% CI 6.0–13.4%) and was lowest in those aged ≥ 65 years 
(3.7%, 95% CI 2.1–6.2%) (Fig. 1). 
Among women aged 15 to 44 years, those with PCOS were 
more likely to report diabetes, cardiovascular disease, and arthritis 
(all p < 0.05) (Table 2). These differences were not significant for 
women aged 45 years and over, however in this age group women 
with PCOS tended to report more diabetes, more asthma and more 
clinical depression symptoms than their non-PCOS peers. 
Table 3 compares the risk of comorbidities and fair/poor self-
assessed health among women who reported PCOS overall and 
those who did not. 
Women with PCOS had a doubling in odds of diabetes (19.0% 
vs. 8.2%, adjOR 2.23, 95% CI 1.49–4.31) and tripling in odds of 
cardiovascular disease (8.2% vs. 4.3%, OR 3.18, 95% CI 1.31, 7.68); 
both findings were robust to adjustment for age and BMI. The 
frequency of other comorbidities or poor/fair self-assessed health 
was not significantly different between groups. 
DISCUSSION
Main findings
This study is one of the first contemporary community-based studies 
examining the diagnosis of PCOS and the health status of affected 
women across the lifespan from adolescence to post-menopause. 
We found the prevalence of diagnosed PCOS peaked in the 35–44 
age group (9.1%), and was lowest in the youngest (15–24 years) and 
oldest (65 and over) groups. PCOS was associated with an increased 
risk of diabetes and cardiovascular disease, independent of BMI, 
however, the excess risk was diminished in women aged 45 years or 
more. 
Table 1. Demographic and lifestyle characteristics of the 











<45 years 695 (46.0) 648 (45.5) 47 (55.6)
≥ 45 years 815 (54.0) 777 (54.5) 38 (44.4)
Country of birth 0.26
Australia 1113 (73.7) 1051 (73.8) 62 (72.4)
UK/Ireland 130 (8.6) 125 (8.8) 4 (5.0)
Other 267 (17.7) 247 (17.4) 19 (22.7)
Aboriginal 0.33
Yes 20 (1.8) 18 (1.8) 2 (2.6)
Education 0.74
No schooling to secondary 625 (41.5) 593 (41.7) 32 (37.7)
Trade, certificate, diploma 507 (33.6) 476 (33.4) 31 (36.9)
Degree or higher 354 (24.9) 354 (24.9) 22 (25.4)
Employment status 0.92
Full time employed 318 (21.0) 301 (21.1) 17 (19.8)
Part time employed 429 (28.4) 495 (28.4) 24 (28.5)
Unemployed 40 (2.6) 37 (2.6) 3 (3.8)
Economically inactive† 723 (47.9) 682 (47.9) 41 (47.9)
Marital status 0.47
Married/Living with partner 954 (63.2) 894 (62.7) 60 (70.6)
Separated/Divorced 150 (10.0) 143 (10.0) 8 (8.9)
Widowed 111 (7.4) 105 (7.4) 6 (6.9)
Never married/other 294 (19.5) 283 (19.9) 12 (13.5)
Ever been pregnant 1088 (73.6) 1020 (73.2) 68 (81.4) 0.09
BMI status 0.04
Underweight/Normal weight 631 (46.7) 606 (47.5) 25 (34.2)
Overweight 370 (27.3) 348 (27.2) 22 (28.9)
Obese 352 (26.0) 324 (25.3) 28 (36.9)
Exercise ≥ 3 days/week 843 (55.9) 794 (55.8) 50 (58.1) 0.68
Current smoker 186 (12.4) 169 (11.9) 17 (19.6) 0.04
† Includes home duties, student, retired, unable to work, others.
*Chi square test  p < 0.05 for the difference between the PCOS and no PCOS groups. 
PCOS: Polycystic ovary syndrome, BMI: body mass index.















Fig. 1. Prevalence of self-reported, doctor-diagnosed PCOS by 10-year age group.






































































































Our findings suggest that there is under diagnosis of PCOS 
among younger and older women, as the clinical features of 
PCOS typically emerge around menarche (Ibanez et al., 2017) and 
many (e.g. elevated testosterone) persist as women age (Winters 
et al., 2000). Underdiagnoses in the younger cohort could reflect 
challenges in consensus criteria to diagnose PCOS in adolescents 
and/or the opinion that it is not appropriate to label girls with a 
diagnosis so early, but rather monitor them. Additionally, the older 
cohort would have been more likely to be diagnosed decades earlier 
during a time at which PCOS was less known or criteria more 
uncertain/controversial. Unfortunately, we did not have access to age 
of diagnosis so we can only speculate on this.
As we relied on self-reported, doctor-diagnosed PCOS, rather 
than participants being clinically examined, the peak in prevalence 
in women aged 35–44 years is likely to reflect diagnoses resulting 
from investigations and treatment for sub- and infertility (Lujan et 
al., 2008) (e.g. clinical guidelines recommend screening for ovulatory 
status in all infertility patients (Rasquin Leon & Mayrin, 2017)). This 
signals opportunities to improve diagnosis and awareness of PCOS 
outside of the reproductive years among both clinicians and women. 
Previous studies indicate that delays in PCOS diagnosis are common, 
with women often seeing more than three health professionals over 
a two-year period before a diagnosis is made (Gibson-Helm et al., 
2017, 2014). 
Interpretations
In our study, women with PCOS overall were more than twice as 
likely to report concurrent diabetes or cardiovascular disease, than 
women without PCOS, irrespective of BMI. However, when stratified 
by age group, the increased risk was most pronounced in women 
pre-menopause. For example, among women aged 45 years or more, 
there was no clear difference in the occurrence of cardiovascular 
disease between groups. These findings may suggest that women 
with PCOS experience an early onset of cardio-metabolic disease, 
however, the gap is reduced as women age, due to the deteriorating 
health of their peers. This is consistent with the limited existing 
Table 2. Physical, metabolic and psychological comorbidities and self-assessed health status in women 
reporting PCOS aged < 45 and ≥ 45 years. 











   Yes 25 (3.8) 8 (16.7) 92 (11.9) 8 (21.9)
   No 623 (96.2) 40 (83.3) 685 (88.1) 30 (78.1)
Cardiovascular disease 0.01* 0.32*
   Yes 4 (0.6) 3 (6.3) 57 (7.4) 4 (10.7)
   No 644 (99.4) 44 (93.7) 719 (92.6) 34 (89.3)
Blood pressure medication use 0.33* 0.14
   Yes 15 (2.3) 2 (3.8) 284 (36.5) 9 (24.7)
   No 633 (97.7) 47 (96.2) 493 (63.5) 28 (75.3)
Cholesterol medication use 0.15* 0.76
   Yes 8 (1.2) 2 (3.7) 194 (25.0) 10 (27.2)
   No 640 (98.8) 47 (96.3) 583 (75.0) 28 (72.8)
Current asthma 0.59 0.05
   Yes 109 (16.9) 9 (19.9) 129 (16.6) 11 (28.9)
   No 538 (83.1) 34 (80.1) 647 (83.4) 27 (71.1)
Arthritis 0.04 0.49
   Yes 47 (7.2) 7 (15.5) 359 (46.4) 20 (52.2)
   No 601 (92.8) 40 (84.5) 415 (53.6) 18 (47.8)
Clinical depression symptoms 0.84 0.08
   Yes 85 (13.2) 7 (14.2) 88 (11.3) 8 (20.6)
   No 562 (86.8) 41 (85.8) 688 (88.7) 30 (79.4)
Anti-depressant use 0.20 0.59
   Yes 103 (16.0) 11 (23.1) 178 (23.0) 10 (26.7)
   No 544 (84.0) 36 (76.9) 598 (77.0) 28 (73.3)
Self-reported health status
Fair/poor 0.60 0.19
   Yes 55 (8.5) 5 (10.5) 170 (21.9) 12 (31.0)
   No 529 (91.5) 42 (89.2) 607 (78.1) 26 (69.0)
Pearson’s chi square test  p < 0.05, for the comparison of women self-reporting PCOS vs. those not reporting PCOS.
* Fisher’s exact test.
adj: Adjusted, BP: blood pressure, PCOS: polycystic ovary syndrome, CI: confidence interval, OR: odds ratio.






































































































research demonstrating there is no difference in mortality from 
cardiovascular disease between women with or without PCOS (Wild 
et al., 2000). Alternatively, while speculative, it is possible that risk is 
mitigated in older women with PCOS (who in our study are likely 
to have had severe symptoms of PCOS resulting in a diagnosis), as a 
result of improved health literacy and access to lifestyle intervention 
in mid to late life as part of PCOS care. 
Our findings are an important expansion to the existing literature 
on the impact of PCOS, as while many studies report an increased 
frequency of risk factors for cardiovascular disease (e.g. obesity, 
dyslipidaemia, hypertension, etc.), few have examined established 
disease (Carmina, 2009). Further research, including longitudinal 
studies in unselected populations, is needed to understand the long-
term consequences of PCOS. 
In this study, women aged <45 years with PCOS were more 
likely to report a concurrent diagnosis of arthritis than their peers. 
While we are not aware of any previous reports of this association, 
it is plausible that inflammation, and/or lack of exercise, linked to 
obesity in PCOS could contribute to an increased risk of arthritis. 
This requires confirmation in future studies, and could identify new 
opportunities to improve the management of this condition.
In our study, approximately 20% of women with self-reported 
PCOS were current smokers, compared to 12% of women who 
did not report PCOS. These findings are inconsistent with another 
Australian community-based study, which reported no difference in 
smoking rates between women with or without PCOS (Htet et al., 
2017; Moran et al., 2017). However, these studies were restricted 
to women aged between 28 to 36 years, coinciding with the peak 
reproductive years, which may underestimate the extent of smoking 
as life experiences such as starting a family can be a strong impetus 
to cease smoking (Fingerhut et al., 1990; Gallus et al., 2013; Kahn 
et al., 2002; Schneider et al., 2010). 
Overall, we found no differences between women with and 
without PCOS in terms of mental health (symptoms of clinical 
depression, use of antidepressants) and self-reported health status. 
This is in contrast to prior studies in clinical populations reporting 
lower self-reported health (Jones et al., 2008) and depression (Deeks 
et al., 2011). However, older women with PCOS tended to report 
more clinical symptoms of depression than their similarly aged peers 
who had not been diagnosed with PCOS (of borderline statistical 
significance). While this requires confirmation, these findings 
underscore the importance of psychological support for women with 
this condition. 
Strengths
The strengths of this study include use of an established, rigorous 
sampling framework that is community based, includes women 
across the lifespan, and results a study sample that is broadly 
representative of the female population aged 15 or more in South 
Australia. The use of this survey as a data collection vehicle provides 
a wider age group than previous Australian studies on PCOS. This 
overcomes the major bias of many existing studies of PCOS that 
are based on infertile clinical populations. Indeed in this study the 
overall prevalence of PCOS was 5.6%, which is highly consistent 
with self-reported prevalence in other community-based cohorts in 
Australia (Joham et al., 2015; March et al., 2010) and internationally 
(Azziz et al., 2004; Michelmore et al., 1999; Nikokavoura et al., 
2015).
Limitations
The study was limited by reliance on self-reported PCOS status, which, 
as discussed above, may underestimate prevalence due to the high 
number of women with PCOS who have not been diagnosed (March 
et al., 2010; Sivayoganathan et al., 2011). We were unable to ascertain 
which PCOS criteria was used for each woman’s diagnosis. Older 
women, particularly those aged 65 and over may have also found it 
difficult to remember about a diagnosis, possibly introducing recall 
bias. In addition, investigations of lifestyle risk factors and comorbid 
conditions stratified by PCOS status and by age were underpowered 
to detect small but clinically meaningful differences due to small cell 
sizes, and should be interpreted with caution. Whilst it may have 
been ideal to have medical records of diagnoses of comorbidities it 
was beyond the scope of the current study. Imprecision may have 
influenced some outcomes, for example women were asked if they 
took antidepressants, and clinical depression was calculated using 
the MCS of the SF12, rather than completing a clinical assessment 
of mental health and wellbeing. However this survey has been 
validated in the Australian population for a number of different 
chronic conditions such as urinary incontinence (Avery et al., 2004, 
2013, 2014), arthritis (Hill et al., 1999), asthma (Adams et al., 2001), 
sleep apnoea (Adams et al., 2012) and depression (Goldney et al., 
2010).
Table 3. Risk of physical, metabolic and psychological comorbidities and fair/poor self-assessed  
health among women reporting PCOS.
OR (95% CI) p-value
OR (95% CI)
adj for age* p-value
OR (95% CI)
adj for age and BMI* p-value
Health conditions
Diabetes 2.62 (1.48, 4.65) 0.001 3.08 (1.71, 5.56) ≤0.001 2.23 (1.49, 4.31) 0.018
Cardiovascular disease 2.01 (0.89, 4.53) 0.093 2.87 (1.21, 6.81) 0.017 3.18 (1.31, 7.68) 0.010
BP medication use 0.57 (0.29, 1.08) 0.082 0.73 (0.35, 1.50) 0.385 0.50 (0.23, 1.12) 0.091
Cholesterol medication  use 0.99 (0.53, 1.87) 0.996 1.49 (0.73, 3.02) 0.274 1.33 (0.63, 2.83) 0.460
Current asthma 1.56 (0.93, 2.61) 0.093 1.55 (0.92, 2.60) 0.098 1.41 (0.80, 2.47) 0.233
Arthritis 1.17 (0.73, 1.87) 0.524 1.63 (0.96, 2.78) 0.073 1.41 (0.78, 2.55) 0.251
Clinical depression symptoms 1.48 (0.82, 2.66) 0.189 1.45 (0.80, 2.60) 0.219 1.34 (0.70, 2.56) 0.372
Anti-depressant use 1.33 (0.80, 2.22) 0.271 1.35 (0.81, 2.25) 0.246 1.19 (0.69, 2.08) 0.525
Self-reported health status
Fair/poor health 0.76 (0.44, 1.33) 0.338 0.69 (0.39, 1.21) 0.192 0.93 (0.49, 1.74) 0.817
adj: Adjusted, PCOS: polycystic ovary syndrome, BMI: body mass index, BP: blood pressure, CI: confidence interval, OR: odds ratio.
* Age and BMI were continuous variables in the regression models.
** Rating dichotomised into excellent, very good or good vs. fair or poor.






































































































Implications for practice and/or policy
It is important to refer to agreed criteria for diagnosis of PCOS in 
adolescents, in order to avoid labelling of younger women, creating 
undue anxiety. Monitoring younger women is more appropriate. 
Further, an adequate diagnosis is necessary in order to encourage 
benefits from early lifestyle or medical interventions. Similarly, it is 
important to investigate new methods of diagnosis in older women, 
and consequently identify risk factors that may be more prevalent 
with PCOS throughout the Lifecourse.
CONCLUSION 
Our community-based study provides important insights into the 
prevalence of PCOS and burden of comorbidities across the lifespan. 
Our findings point to under-diagnosis of this condition in younger 
and peri/post-menopausal women, and identify diabetes and 
CVD as key comorbidities requiring greater attention in younger 
women with PCOS. PCOS is underdiagnosed in younger and older 
women may be related to uncertainty of criteria in younger women/
adolescents as well as lack of awareness of PCOS by practitioners 
in decades prior, leading to lower diagnoses in women that have 
transitioned to the oldest cohort(s). 
Improving timely diagnosis and management of this condition 
is critical, to ensure women receive the most benefit from early 
lifestyle and medical intervention to mitigate the significant risk of 
metabolic complications of PCOS.
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